Randomized trial demonstrates improved solubility of baicalein in inclusion systems, highlighting its potential benefits.
Baicalein (BA) is a poorly water-soluble flavonoid whose limited aqueous solubility restricts its oral bioavailability and pharmaceutical performance. This study aimed to enhance BA solubility and dissolution behavior through the development of binary (BA–β-cyclodextrin) and ternary (BA–β-cyclodextrin–chitosan) inclusion systems. Solid-state characterization was performed using DSC, FTIR and XRD analysis, while thermodynamic evaluation was conducted through Higuchi–Connors phase-solubility analysis. Molecular docking and MM-GBSA calculations were employed to support host–guest interaction mechanisms. Equilibrium solubility studies revealed that pure BA exhibited an intrinsic solubility of 7.50 µg/mL, whereas the optimized 1:2 BA:β-CD binary complex achieved 65.99 µg/mL, corresponding to approximately 8.8-fold enhancement. The phase-solubility diagram displayed an AL-type profile with a calculated apparent stability constant (K_s) of 5.3 × 10 2 M −1 , confirming predominant 1:1 inclusion complex formation. Dissolution studies further demonstrated significantly improved cumulative drug release for binary systems and sustained-release behaviour for ternary complexes. These findings provide integrated thermodynamic, physicochemical, and computational evidence supporting cyclodextrin-assisted solubilization of baicalein and highlight the potential of combined inclusion–polymer systems for improving the pharmaceutical performance of poorly soluble flavonoids.
No takes yet. Share an insight, caveat, or question.
Malkawi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: